Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocklatan vs Latanoprost in Open Angle Glaucoma and Ocular Hypertension
NCT07325240Phase 4Recruiting
- Sponsor
- Mayo Clinic
- Start
- Nov 2025
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of netarsudil + latanoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Mayo Clinic. Primary endpoint: Intraocular Pressure at 2 weeks. Started Nov 2025; status: recruiting.
02
Drugs
netarsudil + latanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT07325240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07325240.